Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: William Whitehead Jr. who wrote (18)	8/14/1998 4:46:00 PM
From: Tim Cruise	Read Replies (1) \| Respond to of 356

William, I appreciate your concerns and will give you my take on the situation. With the relatively recent purchase of Boston based Oncologics, the Company has clearly defined their go-forward strategy and position in the war against cancer. Although there was already considerable in-house cancer-based knowledge, the guys from Oncologics significantly strengthened the team. Obviously, this part of the Company and the ANA product are in their infancy. Prior to this acquisition the Company had focused on two primary, promising products -- Colopath & Fibrostat. These products are obviously at later stages in their development, but the Company still has dedicated, qualified resources devoted to them and continues to advance the science. Naturally, at some point an alliance with a major will be considered to take the products to the market and world. As for current discussions, I think that the prospectus refers to initial contact, although I don't know anymore than that, I would not assume that partners have been "lined" up. Personally, I believe in the core team and am delighted that they have been able to surround themselves with quality people. In the short-term, the price will be a function of a finicky market, but I will be around for the long-term as I like the concepts, the people and the products. Have a good weekend, Tim